Dr Patricia McGettigan
Reader in Clinical Pharmacology and Medical Education (HCC)
Centre: Clinical Pharmacology
Email: firstname.lastname@example.orgTelephone: +44(0) 20 7882 7128
ORCID iD: https://orcid.org/0000-0002-9757-9754
Patricia McGettigan trained in pharmacy and medicine at the University of Dublin, Trinity College. As an Evaluator then Senior Lecturer at the Discipline of Clinical Pharmacology and Toxicology, University of Newcastle, New South Wales, Australia, she was appointed to the Pharmacoeconomics Sub-Committee of the national Pharmaceutical Benefits Advisory Committee, conducted epidemiological studies of cardiovascular side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs), worked as a clinician in general medicine and clinical toxicology, and led the medicine component of the final year undergraduate medical curriculum. Moving to Hull York Medical School in 2007, she co-developed the final year MBBS curriculum, set up and led the interprofessional training ward, prescribing teaching program, and whole-class clinical teaching program and with multidisciplinary colleagues conducted a falls risk management clinic.
She joined Professor Sir Mark Caulfield’s group at the WHRI in 2011 assuming responsibility for clinical pharmacology and therapeutics teaching in the undergraduate medical curriculum, contributing to patient care in the cardiology unit at The Royal London Hospital, and establishing with colleagues in Barts Health NHS Trust a specialist HIV-cardiovascular risk management clinic. Her research is pharmacoepidemiology-focused and includes investigations on the mitigation of non-steroidal anti-inflammatory drug (NSAID)-associated adverse events at the University of Copenhagen, Denmark, as well as collaborations on medicines, access and regulation with colleagues in India and at the University of Newcastle, UK.
In 2016, she was invited to join the European Medicines Agency as a seconded national expert with the Pharmacovigilance and Epidemiology Department where she leads the Patient Registries Initiative. She is a Fellow of the Royal College of Physicians in Ireland and of the Royal Australasian College of Physicians and a Senior Fellow of the Higher Education Academy.
Patricia McGettigan’s research has two primary strands, pharmacoepidemiology and medical education. In pharmacoepidemiology, her work includes primary research in the form of case control studies of NSAID-associated cardiovascular events and on medicines regulation including regulatory system failures in India. Her medical education research includes evaluation of the impact of undergraduate interprofessional training on the subsequent performance of new doctors and the development of methods to evaluate multi-disciplinary team-working skills in hospital settings.
For a full list of publications click here
2013 - 2018
- McGettigan P, Roderick P, Kadam A, Pollock A (2018) Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. BJCP DOI:10.1111/bcp.13503.
- Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A (2018) EU-funded initiatives for Real World Evidence: Descriptive analysis of their characteristics and relevance for regulatory decision-making. BMJ Open; in press May 2018.
- McGettigan P, Roderick P, Kadam A, Pollock A (2017) Access, Watch and Reserve Antibiotics in India: Challenges for WHO stewardship. Lancet GH, DOI: http://dx.doi.org/10.1016/S2214-109X(17)30365-0.
- McGettigan P, Schjerning-Olsen A (2017) NSAIDs for high-risk patients: None, celecoxib, or naproxen?. Lancet 2017; http://dx.doi.org/10.1016/S0140-6736(17)30980-7.
- McGettigan P, Ferner R (2017) PCSK9 Inhibitors for hypercholesterolaemia: New drugs, old problems. BMJ 2017;356:j188 doi: 10.1136/bmj.j188.
- Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Lock Hansen M, Køber L, Torp-Pedersen C, Lamberts. (2015) Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA; 313(8):805-814.
- Schjerning Olsen AM, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Lamberts M. (2015) Impact of PPI treatment on gastrointestinal bleeding associated with NSAID use among post-myocardial infarction patients on antithrombotic therapy - A nationwide study. BMJ 2015; 351:h509.
- McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock A (2015) Use of Fixed Dose Combination (FDC) drugs in India: Central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med; 12(5): e1001826.
- McGettigan P, McKendree J (2015) Interprofessional training for final year healthcare students: a mixed methods evaluation of the impact on ward staff and students of a two-week placement and of factors affecting sustainability
(2015) 15:185. BMC Medical Education. 15:185 DOI 10.1186/s12909-015-0436
- McGettigan P, Henry D (2013) Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLoS Med; doi.org/10.1371/journal.pmed.1001388.
- McGettigan P, McKendree J, Reed N, Holborow S, Deveraux-Walsh C, Mace T (2013) Identifying attributes required by Foundation Year 1 doctors in multidisciplinary teams: A tool for performance evaluation. BMJ Qual Saf 2013;22:225-232.
University of Copenhagen: Dr Anne-Marie Schjerning-Olsen, Dr Morten Lamberts, Professor Gunnar Gislason; University of Newcastle: Dr Petra Sevcikova, Mr Peter Roderick, Professor Allyson Pollock; Indian Council of Medical Research: Professor Nilima Krishsagar.
- Many fixed-dose drug combinations in India lack central regulatory approval
Queen Mary University of London / PLOS Medicine